GSK’s Nucala Submission Accepted by FDA for COPD

GlaxoSmithKline (GB:GSK) has released an update.

GlaxoSmithKline (GSK) has announced that the FDA has accepted its submission for Nucala, a potential new treatment for chronic obstructive pulmonary disease (COPD), marking it as the first biologic with monthly dosing for COPD patients. The submission is bolstered by data from the MATINEE study, which shows Nucala’s efficacy in significantly reducing exacerbations in COPD patients. This development could impact the healthcare market, offering relief to millions affected by COPD and potentially alleviating the financial strain on healthcare systems.

For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.